THANK YOU FOR SUBSCRIBING
Pharma Tech Outlook | Monday, December 26, 2022
Novel approaches in pharmacogenetics are expected to enable the development of tailor-made therapeutics for treating widespread health problems.
FREMONT, CA:Pharmacogenomics is an emerging branch combining pharmacology and genomics for the development of effective doses and safe medications tailored according to an individual patient's genetic makeup. Although there is only limited use of pharmacogenomics, novel approaches are currently undergoing clinical trials. Pharmacogenomics will enable the development of tailor-made therapeutics for treating widespread health issues such as neurodegenerative disorders, cardiovascular disorders, HIV, cancer, asthma, etc.
Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.
Many common diseases with high morbidity and mortality rates have well-known genetic components. The degree to which genetics plays a role in diseases like obesity and diabetes has been predicted. On the other hand, some rare gene mutations can offer a vision into the more complex biological processes. For example, when subjects possess extreme levels of HDL in their blood, one can easily demonstrate the CETP's influence on patients' HDL levels. Moreover, with the advent of pharmacogenomics, the path of relationships between disease states and human genes has now been established, leading to the suitable selection of therapeutic targets.
Today, many academic institutions and pharmaceutical companies are moving towards the investigation of the relationship between disease phenotypes and genetic variations to better categorise disease. Despite the collection of medical phenotypes having linkages with samples of DNA offers a prominent opportunity for examining the genetic variation present in patients.
Investigation of genetic variation is possible through the collection of DNA from specific patients. This is characterised in a study where DNA from a person involved in trials of lipid-lowering demonstrated a swift connection between phenotypic novel lipase gene family and HDL levels. Today, it is easy to cross-examine genome selection depending on phenotypic criteria. Newly developed genotyping technologies can genotype hundreds or thousands of markers with the help of high-density oligonucleotide arrays linked with restriction enzyme-based genomic reduction.
Pharmacogenetics considerably expands the therapy outcomes and drug uses. Medications will be prescribed in low doses under strict monitoring to patients showing a genetic predisposition to their adverse events. This will be helpful for drugs with a narrow therapeutic index like warfarin, which will be started gradually in patients with VKORC1 genotype linked with improved warfarin sensitivity. With the help of pharmacogenetics, it is possible to reduce the number of subjects needed to conduct any experiment, and error chances will be eliminated for many diseases.
On the other hand, clinicians will be able to alleviate possible adverse effects with the aid of genetic information for matching an appropriate drug to a suitable patient at a proper dose. For example, the traditional approach to the management of hypertension involves the trial of numerous anti-hypertensive drugs until the desired blood pressure is achieved with adequate drug tolerability.
More in News